PHARMACOLOGY & THERAPEUTICS

RNA therapy: Are we using the right molecules?

Antifungal drugs: New insights in research & development.

Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy.

Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.

Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity

CD26/DPP4 - a potential biomarker and target for cancer therapy.

Biochemical and physiological importance of the CYP26 retinoic acid hydroxylases.

P53 in kidney injury and repair: Mechanism and therapeutic potentials

Drugging K-RasG12C through covalent inhibitors: Mission possible?

Intestinal microbiome as a novel therapeutic target for local and systemic inflammation.

Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness.

Prostaglandins in asthma and allergic diseases☆

Acute kidney injury overview: From basic findings to new prevention and therapy strategies.

The origin of NMDA receptor hypofunction in schizophrenia.

Lactate/GPR81 signaling and proton motive force in cancer: Role in angiogenesis, immune escape, nutrition, and Warburg phenomenon.

Super-enhancers in cancer.

Lorcaserin: a review of its preclinical and clinical pharmacology and therapeutic potential.

Immune mechanisms mediating abscopal effects in radioimmunotherapy

Stress responses in stromal cells and tumor homeostasis.

Autophagy as a novel therapeutic target in vascular calcification.

Molecular mechanisms of cereblon-based drugs.

Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining.

Modulating Wnt signaling at the root: Porcupine and Wnt acylation.

Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis

Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies

Epigenome modifiers and metabolic rewiring: New frontiers in therapeutics

Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics.

Cognitive dysfunction in major depression: From assessment to novel therapies.

Mast cell tryptase - Marker and maker of cardiovascular diseases.

Fighting against depression with TREK‐1 blockers: Past and future. A focus on spadin

Clioquinol: To harm or heal.

The eye as a novel imaging site in diabetes research

The UGTome: the expanding diversity of UDP glycosyltransferases and its impact on small molecule metabolism.

Use of glucocorticoids in the critical care setting: science and clinical evidence.

Regulation of the phosphoprotein phosphatase 2A system and its modulation during oxidative stress: A potential therapeutic target?

Environmental exposures, stem cells, and cancer.

Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice.

Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis.

Non‐vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: Differences between factor IIa and factor Xa inhibition?

Quenching the fires: Pro‐resolving mediators, air pollution, and smoking

Modulation of retinoid signaling: therapeutic opportunities in organ fibrosis and repair.

Isolevuglandins as mediators of disease and the development of dicarbonyl scavengers as pharmaceutical interventions.

Limiting tumor seeding as a therapeutic approach for metastatic disease.

Are cell‐based therapies for kidney disease safe? A systematic review of preclinical evidence

Role of Neutrophils in Ischemic Heart Failure.

Unraveling cancer lineage drivers in squamous cell carcinomas.

Sarcolemmal α2-adrenoceptors in feedback control of myocardial response to sympathetic challenge.